Viridian Therapeutics
Update in progressVRDN (NasdaqCM)
- Company RatingNeutralCompany RatingCombines sentiment and sustainability signals into an overall assessment of the company.Great · Good · Neutral · At Risk · Poor
- SectorHealthcare
- IndustryBiotechnology
Viridian Therapeutics, Inc. focuses on discovering and developing treatments for serious and rare diseases. It pursues IGF-1R therapies for thyroid eye disease (TED), including Veligrotrug, a humanized monoclonal antibody given intravenously, and Elegrobart, a low-volume, infrequent subcutaneous IGF-1R agent. It also develops an anti-TSHR candidate for Graves’ disease and TED, plus FcRn inhibitors VRDN-006 and VRDN-008. Formerly Miragen Therapeutics, the company was founded in 2010 and is based in Waltham, Massachusetts.
Company score
- Sentiment
- 0.53
- SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
- Environment
- 0.00
- EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
- Social
- 0.46
- Governance
- 0.05
- GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
- Sustainability
- 0.15
- SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
- Impact Score
- 0.34
- Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive
Sort by
Order by
Timeframe
No news articles are available for this company yet.
Unable to load company news.
Loading more news
You're all caught up!